Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer
Using Digital Phenotyping to Optimize Psychosocial Risk Screening and Personalized Care: a Pilot Study in Adolescents and Young Adults With Cancer
1 other identifier
interventional
25
1 country
1
Brief Summary
The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable cancer
Started Jan 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 29, 2025
CompletedFirst Submitted
Initial submission to the registry
September 9, 2025
CompletedFirst Posted
Study publicly available on registry
October 23, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
December 30, 2025
December 1, 2025
1.8 years
September 9, 2025
December 29, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Depressive Symptoms (Beck Depression Inventory - BDI)
The Beck Depression Inventory-II (BDI-II; range 0-63) will be used to measure changes in depressive symptoms among adolescents and young adults over time. Higher scores indicate greater depressive symptom severity.
Baseline, Day 10, 2 months
Secondary Outcomes (7)
Participant Retention Rate (MyPHD App and Wearable Device)
Baseline to 2 months
Adherence to EMA Prompts
Baseline to 2 months
Wearable Device Return and Use Rate
Baseline to 2 months
Change in Anxiety Symptoms (Beck Anxiety Inventory - BAI)
Baseline, Day 10, 2 months
Change in PTSD Symptoms (CROPS)
Baseline
- +2 more secondary outcomes
Study Arms (1)
Digital Phenotyping Arm
EXPERIMENTALAll participants (adolescents and young adults with cancer) will receive the digital phenotyping intervention, which includes wearing a smartwatch and using a smartphone-based EMA app over a 10-day period, with psychosocial assessments at baseline, day 10, and 2 months
Interventions
Participants will wear a wrist-based wearable device for 10 days to passively track physiological data (heart rate, steps, sleep, etc.).
Participants will respond to ecological momentary assessments (EMA) via smartphone to actively report on sleep, mood, stress, and eating habits across a 10-day period.
Eligibility Criteria
You may qualify if:
- years old
- Recent cancer diagnosis (\>2 and \<18 months since diagnosis)
- Willing to carry smartphone on their person for duration of study participation
- Willing to wear smartwatch for duration of study participation
You may not qualify if:
- Significant physical or mental disability that prevents completion of study activities
- Lack of proficiency in English or Spanish
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stanford University
Palo Alto, California, 94304, United States
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Victoria Cosgrove, PhD
Stanford University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 9, 2025
First Posted
October 23, 2025
Study Start
January 29, 2025
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
December 30, 2025
Record last verified: 2025-12